New Delhi: Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets.
The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added.
The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM).
Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.
IPO Alert: ICICI Prudential AMC IPO Opens With Soft Start, Grey Market Premium Steady At ₹120
US: Doorcam Video Shows Exact Moment Of Gas Explosion In California's Hayward; 6 Injured
'No Star Treatment': Preeti Jhangiani Recalls Working With Shah Rukh & Amitabh Bachchan on Mohabbatein- EXCLUSIVE
Pension Fund Regulatory & Development Authority Widens Investment Options For Deploying Funds To Garner Better Returns
(Except for the headline, this article has not been edited by FPJ's editorial team and is auto-generated from an agency feed.)
